Literature DB >> 12766581

The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma.

Teresa Rampino1, Marilena Gregorini, Grazia Soccio, Milena Maggio, Renato Rosso, Paolo Malvezzi, Chiara Collesi, Antonio Dal Canton.   

Abstract

The proto-oncogene product Ron is the receptor for macrophage stimulating protein, a scatter factor that stimulates cell proliferation, prevents apoptosis, and induces an invasive cell phenotype. We investigated the expression of Ron, Ki-67 (proliferation index), p53, and bcl-2 (proapoptotic and antiapoptotic proteins, respectively) in 50 renal tumors (19 clear cell carcinomas, 18 oncocytomas, 7 papillary cell carcinomas, 5 chromophobe cell carcinomas, and 1 carcinoma with sarcomatoid areas). In addition, we studied Ron in normal kidney and in the renal carcinoma cell line Caki-1. Immunostaining and Western blot showed Ron in normal kidney and in all oncocytomas but never in renal cell carcinomas or in Caki-1. In addition, Western blot showed that Ron was expressed in phosphorylated, i.e., active, form. Bcl-2 was strongly expressed in oncocytomas, whereas Ki-67 and p53 were much less expressed in oncocytomas than in carcinomas. These results indicate in Ron a marker that differentiates oncocytoma from the other renal epithelial tumors. We therefore think that Ron may prove to be a new tool for a sound and precise diagnosis of oncocytoma, a benign tumor that cannot always be distinguished from carcinomas at histologic examination. The overexpression of bcl-2, but not p53 in oncocytoma, suggests that the MSP/Ron system sustains the growth of oncocytoma by opposing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766581     DOI: 10.1097/00000478-200306000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma.

Authors:  Naoto Kuroda; Naoki Kanomata; Tadanori Yamaguchi; Yoshiaki Imamura; Chisato Ohe; Noriko Sakaida; Ondrej Hes; Michal Michal; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-06-30       Impact factor: 2.309

2.  Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma.

Authors:  Marco K C Hui; Kenneth K Y Lai; Kwok Wah Chan; John M Luk; Nikki P Lee; Yvonne Chung; Leo C Cheung; Gopesh Srivastava; Sai Wah Tsao; Johnny C Tang; Simon Law
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

3.  Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Mrinal Gounder; Shadia I Jalal; Valérie André; Siva Rama Prasad Kambhampati; Nick Loizos; Jennifer Hall; Timothy R Holzer; Aejaz Nasir; Jan Cosaert; John Kauh; E Gabriela Chiorean
Journal:  Invest New Drugs       Date:  2017-02-04       Impact factor: 3.850

4.  Molecular classification of renal tumors by gene expression profiling.

Authors:  Audrey N Schuetz; Qiqin Yin-Goen; Mahul B Amin; Carlos S Moreno; Cynthia Cohen; Christopher D Hornsby; Wen Li Yang; John A Petros; Muta M Issa; John G Pattaras; Kenneth Ogan; Fray F Marshall; Andrew N Young
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

5.  BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.

Authors:  Laleh Ehsani; Rishie Seth; Stephanie Bacopulos; Arun Seth; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2012-12-15

6.  Expression of claudin-7 in benign kidney and kidney tumors.

Authors:  Lin Li; Jorge L Yao; P Anthony di Sant'Agnese; Patricia A Bourne; Maria M Picken; Andrew N Young; Steven S Shen; Jiaoti Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 7.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 8.  Key clinical issues in renal cancer: a challenge for proteomics.

Authors:  Rosamonde E Banks; Rachel A Craven; Patricia Harnden; Sanjeev Madaan; Adrian Joyce; Peter J Selby
Journal:  World J Urol       Date:  2007-08-25       Impact factor: 4.226

9.  Intron retention in the alternatively spliced region of RON results from weak 3' splice site recognition.

Authors:  Lindsay D Smith; Christian M Lucas; Ian C Eperon
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.